Briefing
An international research team led by the Grupo de Metástasis Cerebral at the Centro Nacional de Investigaciones Oncológicas (CNIO) in Madrid has documented a previously little-described early stage in the development of brain metastases in a study published on 29 September 2026 in the journal Cancer Cell According to the authors, soon after reaching their target organ, disseminated tumour cells undergo a «pausa proliferativa» – a temporary adaptation phase during which they are functionally and molecularly more vulnerable than at later stages.
The researchers first identified this phase in mouse models and validated key features in human samples of micrometastases. In preclinical experiments, the cell populations in question could be targeted with three different drugs; two of these substances are already approved for other indications, according to the study. However, the study explicitly stresses that this is not a treatment option that is immediately available: efficacy, safety and the appropriate time window must be assessed in clinical trials before it can be used in patients.
Key outstanding questions include whether the findings apply to metastases from different primary tumours, which classes of drugs best exploit this particular vulnerability, and the challenge of ensuring drugs can reach the brain in view of the blood–brain barrier. The researchers call for studies on how to time potential drug-based prevention alongside surgery or established follow-up programmes.
Spanish institutions, led by the CNIO in Madrid, played a central role in the experimental design and data analysis; more than seventy researchers from around twenty institutions in Spain, the United Kingdom, Germany, France and the USA took part in the project. If the approach is confirmed in clinical trials, it could have practical implications for follow-up care for patients at high risk of relapse. Until then, the described vulnerability phase is above all a clearly defined scientific target for drug testing and prevention research.
Editor: Andreas M. Brucker (Article created with AI assistance).